Adverse Event Reporting Flashcards
7 cards from real CLE practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 7 Adverse Event Reporting flashcards as text
A breastfeeding mother reports a rash after using a lanolin-based nipple cream. The CLE suspects an allergic contact dermatitis. Which body oversees adverse event reports for this type of topical product?
Answer: FDA Center for Drug Evaluation and Research (CDER) or CFSAN depending on product classification
Nipple creams may be regulated as OTC drugs (CDER) or cosmetics (CFSAN) depending on their claims, so the appropriate FDA center depends on product classification.
Which statement about voluntary versus mandatory adverse event reporting is CORRECT in the US context?
Answer: Manufacturers must report serious device-related events; healthcare providers may report voluntarily
Under FDA regulations, device manufacturers and importers have mandatory reporting obligations, while healthcare professionals and consumers report voluntarily through MedWatch.
After a breastfeeding infant is diagnosed with methemoglobinemia potentially linked to a nipple cleaning solution, the CLE should prioritize which action?
Answer: Preserve the product sample and lot number, then file a MedWatch report
Preserving product evidence and reporting to FDA MedWatch are critical steps when a product is suspected of causing a serious infant adverse event.
A CLE working in a hospital notices a cluster of three infants with feeding difficulties all using the same silicone bottle nipple brand. What is the MOST appropriate escalation?
Answer: Report the cluster to the FDA as a potential signal, referencing all three cases
A cluster of similar adverse events with the same device constitutes a signal that should be formally reported to the FDA to trigger investigation.
Which international framework guides pharmacovigilance standards that may influence how a US-based CLE understands global adverse event reporting?
Answer: WHO Programme for International Drug Monitoring (Uppsala Monitoring Centre)
The WHO Uppsala Monitoring Centre coordinates international pharmacovigilance, establishing global standards that inform drug safety monitoring worldwide.
When a CLE documents an adverse event in a client's electronic health record (EHR), which principle of documentation best supports a future regulatory report?
Answer: Record objective findings with timestamps, product identifiers, and the client's verbatim account
Detailed, contemporaneous EHR documentation with product identifiers and verbatim client statements provides the most defensible basis for regulatory reporting.
A galactogogue herbal supplement causes liver enzyme elevation in a nursing mother. Which FDA reporting program specifically addresses dietary supplement adverse events?
Answer: MedWatch/CFSAN Adverse Event Reporting System (CAERS)
CAERS (CFSAN Adverse Event Reporting System) is the FDA database for adverse events related to foods, dietary supplements, and cosmetics.